Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Views - The company reported a total revenue of 621 million yuan in Q1 2025, a decrease of 4.44% year-on-year, with a net profit attributable to the parent company of 90 million yuan, down 7.41% [1]. - The ophthalmology business faced challenges due to price declines from centralized procurement, while the medical aesthetics sector continued to experience weak terminal consumption [2]. - The company is focused on R&D and innovation, with new products steadily advancing, including approvals for new intraocular lenses and the launch of the fourth-generation hyaluronic acid product "Hai Mei Yue Bai" [2]. - The gross profit margin slightly improved to 69.52% in Q1 2025, attributed to an increase in the proportion of high-margin medical aesthetics products [3]. - The company expects revenue growth to reach 3.103 billion yuan in 2025, with net profit projected at 489 million yuan, reflecting a compound annual growth rate of 16.42% from 2024 to 2025 [4][5]. Summary by Sections Financial Performance - In Q1 2025, the company achieved a gross profit margin of 69.52%, with a net profit margin of 14.60% [3]. - The company reported a stable expense ratio of 51.79%, with sales expenses increasing slightly to 31.35% [3]. - The operating cash flow for Q1 2025 was 86 million yuan, indicating healthy cash flow management [3]. Product Development - The company is advancing its product pipeline, including new medical aesthetics products and intraocular lenses, which are expected to enhance market share [2]. - The innovative "Hai Mei Yue Bai" product is anticipated to address long-standing consumer issues related to hyaluronic acid retention [2]. Market Outlook - The report forecasts revenue growth for the company from 3.103 billion yuan in 2025 to 3.934 billion yuan in 2027, with a corresponding increase in net profit [4][5]. - The company is positioned to benefit from a recovery in the ophthalmology sector as product pipelines expand and centralized procurement impacts stabilize [4].
昊海生物科技（06826）：海魅月白有望逐步放量，医美板块成长动能充足